Recce Pharmaceuticals Ltd (FRA:R9Q)

Market Cap	99.79M +59.7%
Revenue (ttm)	4.19M +49.3%
Net Income	-11.96M
EPS	-0.05
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,000
Average Volume	250
Open	0.3160
Previous Close	0.3220
Day's Range	0.3160 - 0.3160
52-Week Range	0.1290 - 0.4500
Beta	n/a
RSI	45.66
Earnings Date	Feb 27, 2026

About Recce Pharmaceuticals

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. The company’s lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is Phase II clinical trial for the treatment of acute bacterial skin and skin structure infect...

• Industry: Pharmaceutical Preparations
• Founded: 2007
• Country: Australia
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: R9Q

Financial Performance

In fiscal year 2025, Recce Pharmaceuticals's revenue was 7.51 million, an increase of 49.33% compared to the previous year's 5.03 million. Losses were -21.43 million, 21.3% more than in 2024.

Financial numbers in AUD